In 2012, annual revenue from regenerative medicine products surpassed the $1 billion mark. The global regenerative medicine market is predicted to grow to over $35 billion by 2019.
Europe has the second largest regenerative medicine ecosystem in the world with more than 400 companies related to regenerative medicine. Nearly one in three of SMEs active in Europe’s Advanced Therapy Medicinal Product (ATMP) market are based in the UK. Revenues from European sales of stem cell products alone is expected to reach $1.5 billion by 2016.
Opportunities in Regenerative Medicine
Regenerative medicine has the potential to:
Tackle the challenge of an ageing population
Reduce healthcare costs by providing a cure or better management of chronic or hard to treat diseases
Reduce the time and cost of drug development.
Critically we are now seeing the promise of regenerative medicine starting to become a reality with a number of successfully launched products.
Ease of doing business in the UK
The UK Government is committed to creating a supportive business environment for life sciences in the UK, and is focused on catalysing innovation and commercial success. The UK’s regenerative medicine and stem cell sector benefits from a , and the .
The UK’s rich and diverse ecosystem
The UK offers:
Access to world-class resources: funding, research, talent and facilities
Strong supply chain: fast and cost effective – from prototype to scale-up and delivery
High value established manufacturing capabilities
Clinical research infrastructure: efficient clinical trial delivery
Commercial support through partnership with the Cell Therapy Catapult – to accelerate
translation and deliver clinical impact
Gateway to Europe and the global markets, home to MHRA and EMA
Find out more on how you can access the UK Regenerative Medicine and Stem Cells sector by downloading our leaflet.